Selecta Biosciences

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development of cell therapy product candidates. The company is headquartered in Gaithersburg, MD.

Del Taco Restaurants

First American Financial

Triumph Bancorp

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when markets are near all-time highs.

Last Week's Notable Insider Buys: Del Taco, First American And More

The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.

Selecta's (SELB) Gene Therapy Gets Rare Pediatric Disease Tag

Element Solutions Inc

Mission Produce

Immunome

Pulmonx

Last Week's Notable Insider Buys: Element Solutions, Selecta Biosciences And More

Application of ImmTOR™  plus IGAN’s IgA p rotease to target immunoglobulin A ( IgA ) deposition, the critical event leading to IgA N ephropathy ( IgAN )

Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in Combination with IGAN’s IgA Protease for the Treatment of IgA Nephropathy

With a market cap of $171 million (10/1/2020), Selecta Biosciences is a well positioned clinical-stage biotech company, focusing on immunogenicity.

Selecta Biosciences And Selecting One's Battles (Wisely) After The Oct 1st Decline

Horizon Pharma

Shares of Horizon Therapeutics PLC (NASDAQ: HZNP), which focuses on rare and rheumatic diseases, surged higher Thursday despite an absence of announcements from the biopharma. What Happened: Horizon shares moved in sympathy with Selecta Biosciences Inc (NASDAQ: SELB), which announced an adverse mid-stage clinical data readout for SEL-212.

Why Horizon Therapeutics, Selecta Biosciences Are Moving In Sympathy

Disappointing phase 2 data casts doubt on SEL-212's future.

Why Selecta Biosciences Tumbled 34% Today

STOCKHOLM and WATERTOWN, Mass., Sept. 30, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced topline data for the phase 2 COMPARE study comparing the efficacy of SEL-212, a combination of Selecta's...

Sobi and Selecta Biosciences announce topline data of SEL-212 from the phase 2 COMPARE study supporting the potential for important clinical improvement in patients with Chronic Refractory Gout

All data consistent with stronger performance of SEL-212 versus pegloticase

Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Supporting the Potential for Important Clinical Improvement in Patients with Chronic Refractory Gout

STOCKHOLM and WATERTOWN, Mass., Sept. 23, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced the commencement of the phase 3 clinical programme of SEL-212 for chronic refractory gout, with the...

First patient randomised in the phase 3 DISSOLVE clinical programme of SEL-212 for Chronic Refractory Gout

STOCKHOLM, Sweden and WATERTOWN, Mass., Sept.  23, 2020  (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced the commencement of the phase 3 clinical program of SEL-212 for chronic refractory gout, with the randomization of the first patient in the study.

First Patient Randomized in the Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory Gout

WATERTOWN, Mass., Sept.  01, 2020  (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTORTM, today announced that it has entered into a debt financing facility for up to $35 million with Oxford Finance and Silicon Valley Bank (SVB). Proceeds from the financing will be used to retire $12.6 million of existing debt, advance Selecta’s ImmTOR pipeline in gene therapy and autoimmune diseases, and for selected business development activities.

Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Valley Bank

Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q2 2020 Results - Earnings Call Transcript

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -153.13% and -100.00%, respectively, for the quarter ended June 2020.

Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Lags Revenue Estimates

Selecta Biosciences (SELB) miss estimates for earnings and revenues in the second quarter of 2020.

Selecta Biosciences (SELB) Q2 Earnings & Sales Miss Estimates

WATERTOWN, Mass., Aug.  06, 2020  (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR, today reported financial results for the second quarter ended June 30, 2020 and provided corporate updates.

Selecta Biosciences Reports Second Quarter 2020 Financial Results  and Provides Corporate Updates

In the absence of any marketed drugs, investor focus is likely to be on Selecta Biosciences' (SELB) lead pipeline candidate, SEL-212 on the second-quarter conference call.

What Awaits Selecta Biosciences (SELB) This Earnings Season?

WATERTOWN, Mass., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced the appointment of Peter G. Traber, MD, to the position of Chief Medical Officer. Dr. Traber has been serving in the same position in an interim capacity, and joins the Company full-time, effective August 1, 2020.

Selecta Biosciences Appoints Peter G. Traber, MD as Chief Medical Officer

WATERTOWN, Mass., July  30, 2020  (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to host a conference call on Thursday, August 06, 2020, at 8:30 a.m. Eastern Time to discuss its financial results for the second quarter and recent operational highlights.

Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter Financial Results and Recent Operational Highlights

STOCKHOLM, Sweden and WATERTOWN, Mass., July  28, 2020  (GLOBE NEWSWIRE) --  Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI ) today announced that the strategic licensing agreement with  Selecta Biosciences, Inc.  (Nasdaq: SELB) for SEL-212, entered into as earlier announced on June 11, 2020, became effective on July 28, 2020, following the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period.

Sobi and Selecta announce closing of previously announced strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout

Is  (SELB) Outperforming Other Medical Stocks This Year?

Is Selecta Biosciences (SELB) Outperforming Other Medical Stocks This Year?

Mesoblast

These two healthcare stocks are risky, but they have much better chances of success than penny stocks.

About to Buy Penny Stocks? Look at These 2 Companies First

Partnership strategy for ImmTOR platform continues to pay off with Sarepta deal immediately following $100 million upfront Sobi deal.

Selecta Biosciences Continues To Attract Partners As Sarepta Therapeutics Signs On For Gene Therapy

Selecta Biosciences (SELB) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Selecta Biosciences (SELB) in Focus: Stock Moves 7.4% Higher

A bullish article is sending shares higher.

News for Selecta Biosciences Stock (SELB)